Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 15, 2004, Pages 3730-3743

  Terasaka, Tadashi ^a   Kinoshita, Takayoshi ^a   Kuno, Masako ^a   Seki, Nobuo ^a   Tanaka, Kohichiro ^a   Nakanishi, Isao ^a,b  

^a ASTELLAS PHARMA INC   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [1 HYDROXY 4 [6 (3 PHENYLPROPOXY)INDOL 1 YL] 2 BUTYL]IMIDAZOLE 4 CARBOXAMIDE; 1 [1 HYDROXY 4 [6 (4 PHENYLBUTOXY)INDOL 1 YL] 2 BUTYL]IMIDAZOLE 4 CARBOXAMIDE; 1 [1 HYDROXY 4 [6 [3 (1 METHYLBENZIMIDAZOL 2 YL)PROPIONYLAMINO]INDOL 1 YL] 2 BUTYL]IMIDAZOLE 4 CARBOXAMIDE; 1 [4 (6 HEXANOYLAMINOINDOL 1 YL) 1 HYDROXY 2 BUTYL]IMIDAZOLE 4 CARBOXAMIDE; 1 [4 [5 [3 (4 CHLOROPHENYL)PROPOXY] 1 METHYLINDOL 3 YL] 1 HYDROXY 2 BUTYL]IMIDAZOLE 4 CARBOXAMIDE; AMIDE; BENZENE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CARBENE; INDOLE DERIVATIVE; PROPANE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL BINDING; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSFORMATION; HYDROPHOBICITY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADENOSINE DEAMINASE; AMIDES; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; IMIDAZOLES; INDOLES; MALE; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 3142654156     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0306374     Document Type: Article

References (35)

1. Cronstein, B. N. Adenosine, An endogenous antiinflammatory agent. J. Appl. Physiol. 1994, 76, 5-13.
2. Ohta, A.; Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414, 916-920.
3. (a) Rudolphi, K. A.; Schubert, P.; Parkinson, F. E.; Fredholm, B. B. Neuroprotective role of adenosine in cerebral ischemia. Trends. Pharmacol. Sci. 1992, 13, 439-445.
4. (b) Marquardt, D. L.; Gruber, H. E.; Wasserman, S. I. Adenosine release from stimulated mast-cells. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 6192-6196.
5. (c) Filippini, A.; Taffs, R. E.; Sitkovsky, M. V. Extracellular ATP in T-lymphocyte activation: Possible role in effector functions. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8267-8271.
6. (a) Cronstein, B. N.; Naime, D.; Ostad, E. The antiinflammatory mechanism of Methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 1993, 92, 2675-2682.
7. (b) Cronstein, B. N.; Montesinos, M. C.; Weissmann, G. Sites of action for future therapy: an adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFκB knockout mice. Osteoarthritis Cartilage 1999, 7, 361-363.
8. (c) Cronstein, B. N.; Montesinos, M. C.; Weissmann, G. Salycylates and sulfasalazine but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkB. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 6377-6381.
9. Cristalli, G.; Costanzi, S.; Lambertucci, C.; Lupidi, G.; Vittori, S.; Volpini, R.; Camaioni, E. Adenosine deaminase: Functional implications and different classes of inhibitors. Med. Res. Rev. 2001, 21, 105-128.
10. Resta, R.; Thompson, L. F. SCID: the role of adenosine deaminase deficiency. Immunol. Today 1997, 18, 371-374.
11. Kameoka, J.; Tanaka, T.; Nojima, Y.; Schlossman, S. F.; Morimoto, C. Direct association of adenosine deaminase with T cell activation antigen, CD26. Science 1993, 261, 466-469.
12. (a) Franco, R.; Valenzuela, A.; Lluis, C.; Blanco, J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol. Rev. 1998, 161, 27-42.
13. (b) Morimoto, C.; Schlossman, S. F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 1998, 161, 55-70.
14. Agerwal, R. P.; Spector, T.; Parks, R. E. Tight-binding inhibitors IV. Inhibition of adenosine deaminase by various inhibitors. Biochem. Pharmacol. 1977, 26, 359-367.
15. Rafel, M.; Cervantes, F.; Beltran, J. M.; Zuazu, J.; Nieto, L. H.; Rayon, C.; Talavera, J. G.; Montserrat, E. Deoxycoformycin in the treatment of patients with hairy cell leukemia. Cancer 2000, 88, 352-357.
16. Brogden, R. N.; Sorkin, E. M. Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993, 46, 652-677.
17. McConnell, W. R.; Furner, R. L.; Hill, D. L. Pharmacokinetics of 2′-deoxycoformycin in normal and L1210 leukemic mice. Drug Metab. Dispos. 1979, 7, 11-13.
18. Lathia, C.; Fleming, G. F.; Meyer, M.; Ratain, M. J.; Whitfield, L. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother. Pharmacol. 2002, 50, 121-126.
19. (a) Baker, D. C.; Hanvey, J. C.; Hawkins, L. D.; Murphy, J. Identification of the bioactive enantiomer of erythro-3-(adenine-9-yl)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Biochem. Pharmacol. 1981, 30, 1159-1160.
20. (b) Bessodes, M.; Bastian, G.; Abushanab, E.; Panzica, R. P.; Berman, S. F.; Marcaccio, E. J.; Chen, S. F.; Stoeckler, J. D.; Parks, R. J. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem. Pharmacol. 1982, 31, 879-882.
21. Cristalli, G.; Eleuteri, A.; Franchetti, P.; Grifantini, M.; Vittori, S.; Lupidi, G. Adenosine deaminase inhibitors: Synthesis and structure-activity relationships of imidazole analogue of erythro-9-(2-hydroxy-3-nonyl) adenine. J. Med. Chem. 1991, 34, 1187-1192.
22. Pragnacharyulu, P. V. P.; Varkhedkar, V.; Curtis, M. A.; Chang, I. F.; Abushanab, E. Adenosine deaminase inhibitors: Synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9- (2′S-hydroxy-3′R-nonyl) adenine [(+)-EHNA]. J. Med. Chem. 2000, 43, 4694-4700.
23. 14C] adenine in the rhesus monkey. Drug Metab. Dispos. 1980, 8, 5-7.
24. Lambe, C. U.; Nelson, D. J. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl) adenine in CBA mice. Biochem. Pharmacol. 1982, 31, 535-539.
25. Terasaka, T.; Nakanishi, I.; Nakamura, K.; Eikyu, Y.; Kinoshita, T.; Nishio, N.; Sato, A.; Kuno, M.; Seki, N.; Sakane, K. Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1115-1118.
26. Terasaka, T.; Kinoshita, T.; Kuno, M.; Nakanishi, I. A highly potent non-nucleoside adenosine deaminase inhibitor: Efficient drug discovery by intentional lead hybridization. J. Am. Chem. Soc. 2004, 126, 34-35.
27. Agerwal, R. P. Inhibitors of adenosine deaminase. Pharmacol. Ther. 1982, 17, 399-429.
28. Alberg, D. G.; Schreiber, S. L. Structure-based design of a cyclophilin-calcineurin bridging ligand. Science 1993, 262, 248-250.
29. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
30. Smith, D. A.; Jones, B. C.; Walker, D. K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 1996, 16, 243-266.
31. Terasaka, T.; Seki, N.; Tsuji, K.; Nakanishi, I.; Kinoshita, T.; Nakamura, K. WO 00/55155, 2000.
32. Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K. S.; Kwong, H. L.; Morikawa, K.; Wang, Z. M.; Xu, D. Q.; Zhang, X. L. The osmium-catalyzed asymmetric dihydroxylation: A new ligand class and a process improvement. J. Org. Chem. 1992, 57, 2768-2771.
33. Kinoshita, T.; Nishio, N.; Sato, A.; Murata, M. Crystallization and preliminary analysis of bovine adenosine deaminase. Acta Crystallogr. 1999, D55, 2031-2032.
34. Navaza, J. On the computation of the fast rotation function. Acta Crystallogr. 1993, D49, 588-591.
35. Kinoshita, T.; Nishio, N.; Nakanishi, I.; Sato, A.; Fujii, T. Crystal structure of bovine adenosine deaminase complexed with 6-hydroxyl-1,6- dihydropurine riboside. Acta Crystallogr. 2003, D59, 299-303.